Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Henagliflozin versus dapagliflozin in overweight or obese adults with type 2 diabetes mellitus and HFrEF
ChiCTR2400087295Phase 4Not yet recruiting
- Sponsor
- The First Affiliated Hospital of University of Science and Technology of China
- Start
- Jul 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of henagliflozin and dapagliflozin in type 2 diabetes mellitus (T2DM) and heart failure with reduced ejection fraction (HFrEF) (2 arms), sponsored by The First Affiliated Hospital of University of Science and Technology of China. Primary endpoint: Proportion of readmission due to heart failure within 12 months. Planned start Jul 2024; status: not yet recruiting.
02
Drugs
henagliflozindapagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)heart failure with reduced ejection fraction (HFrEF)
Beyond the preview
Go deeper on ChiCTR2400087295.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400087295.